- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05589909
Performance of Interleukin-27 Cord Blood Level as A Biomarker Predicating Early Onset Neonatal Sepsis
Neonatal sepsis still considered as one of the major causes of mortality and morbidity during the neonatal period due to high vulnerability of that age group. The blood culture is considered as the gold standard for diagnosis of bacterial sepsis, however in early onset neonatal sepsis (EONS) the inability to isolate a microbial pathogen does not exclude sepsis. The reason behind the high number of culture-negative cases is not clear and might be attributed to low levels of bacteremia or small volumes of blood obtained from sick infants. Also maternal antibiotic treatment before or during delivery may theoretically mask detection of bacteremia in the newborn. In addition these cultures have a 48-72 hours delay to obtain results. Therefore, the combination of clinical assessment and laboratory biomarkers currently are the bases for diagnosis of neonatal sepsis.
Recently interleukin-27 (IL-27) has been looked at as another candidate biomarker in the serum for diagnosis of sepsis in both adult and children. Interleukin-27 (IL-27), a novel member of the IL-12 family, was first discovered in 2002. IL- 27 is primarily synthesized by antigen-presenting cells, and it is widely expressed in a myriad of cells, including placental trophoblast cells. Although multiple studies have reported IL-27 as an essential regulator of immune response and inflammation, its precise role in the immune response is still disputable.
Conventionally, IL-27 has been envisaged as a potent promoter of inflammation. When first discovered, it was characterized as a promoting factor in the rapid initiation of inflammatory responses, processing the ability to stimulate the rapid expansion of naïve CD4+T and then the production of IFN-?, which has been demonstrated by various subsequent studies.
The aim of this study was to evaluate the usage of elevated IL-27 in cord blood as an early predictor biomarker for EONS.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
A prospective study will be conducted in the neonatal intensive care unit (NICU), Mansoura University Children Hospital -over a period of one year. The study subjects will include all newborn infants born to pregnant women with one or more of antenatal risk factors for sepsis including maternal fever, prolonged rupture of membranes with leakage of amniotic fluid preceding the onset of labor for 18 hours or more, presence of chorioamnionitis or evidence of maternal colonization with group B streptococcus (GBS). Prematurity was defined as gestational age of 36+6 weeks and less.
Blood samples for biomarkers detection will be collected from the umbilical artery after clamping the umbilical cords before delivery of the placenta. The blood will be collected in ethylene diamine tetra-acetic acid-containing tubes from each infant for immunological detection of IL-27, procalcitonin and C-reactive protein.
For neonatal blood culture, blood samples will be collected from each neonate, before starting any antimicrobial treatment, by venous puncture from a peripheral vein for blood culture. About 1 mL of blood will be directly inoculated into a pediatric blood culture bottle and sent to the Medical Microbiology and Immunology Department, Mansoura University, Egypt for subsequent microbiological processing. Obtained bacterial isolates will be identified by standard microbiological techniques
Study Type
Enrollment (Anticipated)
Contacts and Locations
Study Contact
- Name: wael seliem, MD
- Phone Number: 00971545873838
- Email: wseliem@hotmail.com
Study Contact Backup
- Name: Amira Sultan, MD
- Phone Number: +971507759539
- Email: amira110sultan@yahoo.com
Study Locations
-
-
-
Abu Dhabi, United Arab Emirates
- Recruiting
- Mansoura University Children Hospital
-
Contact:
- wael seliem, MD
- Phone Number: 0545873838
- Email: wseliem@hotmail.com
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- All newborn infants born to pregnant women who had one or more of antenatal risk factors for sepsis. on or evidence of maternal colonization with group B streptococcus (GBS).
Exclusion Criteria: None
-
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Infection Group
Both suspected and confirmed sepsis occurred ≤72 hours after delivery were counted as cases of EONS.
|
magnetic bead multiplex platform
|
None Infection Group
No evidence clinical or laboratory of infection
|
magnetic bead multiplex platform
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Measurement of IL27, PCT and CRP levels in umbilical cord blood
Time Frame: 6 months
|
comparison between 2 groups
|
6 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Measurement of IL27, PCT and CRP levels in blood after 24 hours
Time Frame: 6 months
|
comparison between 2 groups
|
6 months
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- R.22.03.1667
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Neonatal Sepsis, Early-Onset
-
prof. dr. Frans B. PlötzDutch Society of Pediatrics; Zorgevaluatie Nederland; Care4Neo; everywhereIMRecruitingEOS | Early-Onset Sepsis, NeonatalNetherlands
-
Yale UniversityWithdrawnA Pilot Randomized Controlled Trial for Antibiotic Exposure in Neonatal Sepsis Using Neutrophil CD64Neonatal Early-onset Sepsis | Neonatal Late-onset SepsisUnited States
-
Jip GroenInBiomeRecruitingMicrobial Colonization | Neonatal Infection | Neonatal Sepsis, Early-Onset | Microbial Disease | Clinical Sepsis | Culture Negative Neonatal Sepsis | Neonatal Sepsis, Late-Onset | Culture Positive Neonatal SepsisNetherlands
-
NICHD Neonatal Research NetworkEunice Kennedy Shriver National Institute of Child Health and Human Development... and other collaboratorsCompletedInfant, Newborn, Diseases | Early Onset Neonatal Sepsis | Early-Onset MeningitisUnited States
-
Shandong UniversityShandong Provincial HospitalRecruitingEarly-Onset Neonatal SepsisChina
-
Shandong UniversityShandong Provincial Hospital; Qianfoshan Hospital; Tianjin Central Hospital of...Recruiting
-
Luzerner KantonsspitalCompleted
-
University of TartuEstonian Science Foundation; European Society for Paediatric Infectious DiseasesCompletedEarly Onset Neonatal SepsisEstonia
-
Ulrikka NygaardUniversity of Copenhagen; Innovation Fund DenmarkRecruitingAntibiotic Side Effect | Early-Onset Neonatal SepsisDenmark
-
Academisch Medisch Centrum - Universiteit van Amsterdam...Not yet recruitingEarly-Onset Neonatal Sepsis
Clinical Trials on IL27, PCT, CRP, Blood culture
-
University of Roma La SapienzaUnknownAcute DiverticulitisFrance, Italy
-
Osijek University HospitalCompletedSepsis | Gram-negative Bacteremia | Gram-Positive BacteremiaCroatia
-
Centre Hospitalier Henri Duffaut - AvignonRecruitingCOVID-19 Acute Respiratory Distress SyndromeFrance
-
Beckman Coulter, Inc.CompletedSepsis | Severe Sepsis | Severe InfectionFrance, Spain
-
Suez Canal UniversityMansoura UniversityCompleted
-
Brno University HospitalUnknown
-
Federal University of Minas GeraisWithdrawnCommunity-acquired PneumoniaBrazil
-
Charles University, Czech RepublicActive, not recruitingInflammation | Burns | Infection, BacterialCzechia
-
Gertrud Baunbaek EgelundUnknownCommunity Acquired PneumoniaDenmark
-
Liverpool School of Tropical MedicineREACH Ethiopia; Bingham UniversityCompleted